Exscientia

Exscientia builds artificial intelligence platforms to design and discover new medicines.

Oxford, UK—Website

£283MTotal raised

Exscientia is a clinical stage pharmatech company that uses artificial intelligence to design patient based drugs. The company operates an automated platform to advance precision medicines from target identification to clinical trials.

Team

Andrew Hopkins

CEO

Investors

Series D+27 April 2021
£162M
SV
SoftBank Vision FundLead
Novo HoldingsFollow-on
B
Blackrock
MI
Mubadala Investment Company
FC
Farallon Capital
CC
Casdin Capital
GH
GT Healthcare CapitalFollow-on
MW
Marshall Wace
Pb
Pivotal bioVenture Partners
LC
Laurion Capital
H
Hongkou
BM
Bristol Myers SquibbFollow-on
Series C4 March 2021
$72.2M
B
BlackRock
Novo HoldingsFollow-on
EvotecFollow-on
BM
Bristol Myers SquibbFollow-on
GH
GT Healthcare CapitalFollow-on
Series C26 May 2020
£49.0M
Novo HoldingsLead
Evotec
BM
Bristol Myers Squibb
GH
GT Healthcare Capital

Funding history

Series D+27 April 2021

£162M

Exscientia secures £162m Series D funding led by SoftBank Vision Fund 2

The financing was led by SoftBank Vision Fund 2 with participation from Novo Holdings and Blackrock to expand the proprietary drug pipeline.

Series C4 March 2021

$72.2M

Exscientia raises £21.5m from BlackRock to support its artificial intelligence drug discovery platform

BlackRock joined the Series C round alongside existing investors to bring total financing to $100m.

Series C26 May 2020

£49.0M

Exscientia secures £49m Series C investment led by Novo Holdings to scale operations

Novo Holdings led the financing round to support portfolio expansion and international growth.